cladribine has been researched along with Demyelinating Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casset-Semanaz, F; Comi, G; Coyle, PK; Cree, BA; Freedman, MS; Hartung, HP; Leist, TP; Scaramozza, M; Vermersch, P | 1 |
| Cook, SD; Solanky, M; Van Engel, D; Wolansky, L | 1 |
1 review(s) available for cladribine and Demyelinating Diseases
| Article | Year |
|---|---|
Aggressive central nervous system demyelination in an adolescent.
Topics: Adolescent; Cladribine; Demyelinating Diseases; Diagnosis, Differential; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Severity of Illness Index | 2005 |
1 trial(s) available for cladribine and Demyelinating Diseases
| Article | Year |
|---|---|
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Topics: Administration, Oral; Adolescent; Adult; Cladribine; Demyelinating Diseases; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Time Factors; Treatment Outcome; Young Adult | 2014 |